MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Well being Corp. (TSXV: MDX), (“MedX” or the “Firm”), a world chief in teledermatology and non-invasive pores and skin evaluation, at the moment introduced the appointment of Dr. Symon D. Cotton, achieved medical system innovator and co-developer of SIAscopy®, as Strategic Advisor to the Firm.
Dr. Cotton is an skilled writer and chief in medical know-how innovation, at present serving as Head of Life Sciences at a number one know-how group. His profession has been outlined by work on the intersection of engineering, biology and computation, the place he has efficiently guided quite a few corporations via the event of novel medical units and digital well being platforms.
As one of many key scientific architects of Spectrophotometric Intracutaneous Evaluation (SIAscopy®), Dr. Cotton collaborated with Dr. Paul Matts in its early improvement and codification. Collectively, they helped set up SIAscopy because the world’s first know-how to allow the simultaneous, non-invasive measurement of melanin, hemoglobin and collagen throughout the pores and skin. Their work supplied the inspiration for SIAscopy’s medical adoption in dermatology and its integration into MedX’s DermSecure® platform.
Past his foundational contributions, Dr. Cotton’s experience extends to making use of AI-driven analytics to medical imaging and diagnostics, a talent set instantly aligned with MedX’s strategic roadmap. His management in computational biology, system design, and translational drugs equips MedX to additional improve its AI fashions educated on SIAscopy’s uniquely wealthy imaging datasets, driving larger diagnostic accuracy and scalability.
“I’m proud to have been a part of the unique SIAscopy journey and excited to rejoin the sphere with MedX at such a pivotal second,” mentioned Dr. Cotton. “With AI poised to rework teledermatology, I look ahead to serving to MedX leverage its unmatched imaging database and DermSecure® platform to enhance early pores and skin most cancers detection worldwide.”
John Gevisser, CEO of MedX Well being, added: “Dr. Cotton’s contribution to SIAscopy was instrumental in shaping the know-how that underpins MedX’s international teledermatology platform at the moment. His experience in medical system innovation and computational and AI technique will assist us to increase our management on the forefront of pores and skin optics and machine studying, guaranteeing MedX options stay each clinically rigorous and commercially scalable.”
About MedX Well being Corp.
MedX Well being Corp., headquartered in Ontario, Canada, is a pacesetter in non-invasive pores and skin evaluation and teledermatology. Its proprietary SIAscopy® know-how, built-in into the DermSecure® platform, permits pain-free, correct imaging of pores and skin lesions for speedy dermatologist overview. These merchandise are cleared by Well being Canada, the U.S. Meals and Drug Administration, the Therapeutic Items Administration and Conformité Européenne, to be used in 38 territories worldwide together with Canada, the U.S., Australia, New Zealand, the UK, the European Union and Turkey. MedX’s superior telemedicine platform permits healthcare professionals to rapidly and precisely assess suspicious moles, lesions, and different pores and skin circumstances via its proprietary imaging know-how, SIAscopy®, and its safe, cloud-based affected person administration system, DermSecure®.
Go to: https://www.medxhealth.com
Neither TSX Enterprise Alternate nor its Regulation Providers Supplier (as that time period is outlined in insurance policies of the TSX Enterprise Alternate) accepts accountability for the adequacy or accuracy of this launch.
This Media Launch might include forward-looking statements, which replicate the Firm’s present expectations relating to future occasions. The forward-looking statements contain dangers and uncertainties.
Contacts
MedX Well being Corp.
John Gevisser, CEO – MedX Well being Corp.
john.gevisser@medxhealth.com
(+1) 905-670-4428
MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Well being Corp. (TSXV: MDX), (“MedX” or the “Firm”), a world chief in teledermatology and non-invasive pores and skin evaluation, at the moment introduced the appointment of Dr. Symon D. Cotton, achieved medical system innovator and co-developer of SIAscopy®, as Strategic Advisor to the Firm.
Dr. Cotton is an skilled writer and chief in medical know-how innovation, at present serving as Head of Life Sciences at a number one know-how group. His profession has been outlined by work on the intersection of engineering, biology and computation, the place he has efficiently guided quite a few corporations via the event of novel medical units and digital well being platforms.
As one of many key scientific architects of Spectrophotometric Intracutaneous Evaluation (SIAscopy®), Dr. Cotton collaborated with Dr. Paul Matts in its early improvement and codification. Collectively, they helped set up SIAscopy because the world’s first know-how to allow the simultaneous, non-invasive measurement of melanin, hemoglobin and collagen throughout the pores and skin. Their work supplied the inspiration for SIAscopy’s medical adoption in dermatology and its integration into MedX’s DermSecure® platform.
Past his foundational contributions, Dr. Cotton’s experience extends to making use of AI-driven analytics to medical imaging and diagnostics, a talent set instantly aligned with MedX’s strategic roadmap. His management in computational biology, system design, and translational drugs equips MedX to additional improve its AI fashions educated on SIAscopy’s uniquely wealthy imaging datasets, driving larger diagnostic accuracy and scalability.
“I’m proud to have been a part of the unique SIAscopy journey and excited to rejoin the sphere with MedX at such a pivotal second,” mentioned Dr. Cotton. “With AI poised to rework teledermatology, I look ahead to serving to MedX leverage its unmatched imaging database and DermSecure® platform to enhance early pores and skin most cancers detection worldwide.”
John Gevisser, CEO of MedX Well being, added: “Dr. Cotton’s contribution to SIAscopy was instrumental in shaping the know-how that underpins MedX’s international teledermatology platform at the moment. His experience in medical system innovation and computational and AI technique will assist us to increase our management on the forefront of pores and skin optics and machine studying, guaranteeing MedX options stay each clinically rigorous and commercially scalable.”
About MedX Well being Corp.
MedX Well being Corp., headquartered in Ontario, Canada, is a pacesetter in non-invasive pores and skin evaluation and teledermatology. Its proprietary SIAscopy® know-how, built-in into the DermSecure® platform, permits pain-free, correct imaging of pores and skin lesions for speedy dermatologist overview. These merchandise are cleared by Well being Canada, the U.S. Meals and Drug Administration, the Therapeutic Items Administration and Conformité Européenne, to be used in 38 territories worldwide together with Canada, the U.S., Australia, New Zealand, the UK, the European Union and Turkey. MedX’s superior telemedicine platform permits healthcare professionals to rapidly and precisely assess suspicious moles, lesions, and different pores and skin circumstances via its proprietary imaging know-how, SIAscopy®, and its safe, cloud-based affected person administration system, DermSecure®.
Go to: https://www.medxhealth.com
Neither TSX Enterprise Alternate nor its Regulation Providers Supplier (as that time period is outlined in insurance policies of the TSX Enterprise Alternate) accepts accountability for the adequacy or accuracy of this launch.
This Media Launch might include forward-looking statements, which replicate the Firm’s present expectations relating to future occasions. The forward-looking statements contain dangers and uncertainties.
Contacts
MedX Well being Corp.
John Gevisser, CEO – MedX Well being Corp.
john.gevisser@medxhealth.com
(+1) 905-670-4428
